An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

作者：Lee Hye Won; Park Jun Yong; Ahn Sang Hoon^*

来源：Expert Review of Gastroenterology and Hepatology, 2016, 10(2): 177-186.

DOI：10.1586/17474124.2016.1125781

• Chronic hepatitis B
• entecavir
• long-term therapy
• safety

Entecavir is a nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naive patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.

• 出版日期2016-2-1